BASB054 polypeptides

Details BASB054 polypeptides BASB054 polypeptides

2004-07-12

2010-02-16

Mondesi, Robert B (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S249100, C424S190100, C424S185100, C424S184100, C435S252300, C435S243000, C435S069700, C435S069300, C530S350000, C530S300000, C536S024320, C536S024100, C536S023700

Reexamination Certificate

active

07662399

ABSTRACT:
The invention provides BASB047, BASB054, BASB068 and BASB069 polypeptides, and polynucleotides encoding BASB047, BASB054, BASB068 and BASB069 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

REFERENCES:
patent: 2005/0191316 (2005-09-01), Fraser et al.
patent: 2007/0026021 (2007-02-01), Fraser et al.
patent: WO9802547 (1998-01-01), None
patent: WO99/24578 (1999-05-01), None
patent: WO 99/57280 (1999-11-01), None
patent: WO 00/22430 (2000-04-01), None
patent: WO00/66791 (2000-11-01), None
patent: WO 03/018052 (2003-03-01), None
patent: WO 2005/064021 (2005-07-01), None
Holmes (Exp. Opin.Invest. Drugs, 2001, 10(3):511-519).
Greenspan et al (Nature Biotechnology, 1999, 7:936-937).
Roitt et al (Immunology, 1993, Mosby, St. Louis, p. 7.7-7.8).
Herbert et al (The Dictionary of Immunology, Academic Press, 3rd Edition, London, 1985, pp. 58-59).
Bowie et al (Science, 1990, 257:1306-1310).
Lederman et al (Molecular Immunology 28:1171-1181, 1991).
Li et al (Proc. Natl. Acad. Sci. USA 77:3211-3214, 1980).
Herbert et al (The Dictionary of Immunology, Academic Press, 3rd Edition, London, 1985, pp. 58-59.
European Search Report from EP00901121 dated Aug. 17, 2006.
Martin D et al: “Highly ConservedNeisseria meningitidisSurface Protein Confers Protection Against Experimental Infection” Journal of Experimental Medicine, vol. 185, No. 7.
Lissolo L et al: “Evaluation of Transferrin-Binding Protein 2 Within . . . ” Infection and Immunity, vol. 63, No. 4, Mar. 1995, pp. 884-890.
Sato Y et al: “Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization” Science, vol. 273, Jul. 19, 1986 pp. 352-354.
Chee M et al: “Accessing Genetic Information with High-Density DNA Arrays” Science, vol. 274, Oct. 25, 1996 pp. 610-614.
Infection and Immunity 32, (1981) 592-599.
Infection and Immunity 62, (1991) 3017-3021.
Infection and Immunity 56, (1998) 977-983.
International Search Report for PCT/EP00/00428 (Dec. 7, 2000).
International Preliminary Examination Report for PCT/EP00/00428 (Jan. 15, 2001).
Rudinger et al., in “Peptide Hormones”, edited by Parsons, J.A., University Park Press, Jun. 1976, p. 6.
Burgess et al. , The Journal of Cell Biology, 111:2129-2138, 1990.
Lazar et al., Molecular and Cellular Biology, 8(3): 1247-1252, 1989.
Jobling et al., Mol. Microbiol. 1991, 5(7):1755-67.
Ellis, R.W. Chapter 29 of “Vaccines”, Plotkin et al. (eds) published by W.B. Saunders Company (Philadelphia) in 1988.
Ala'Aldeen, D.A.A., Biotecnologia Aplicada 1996, vol. 13, 1-7.
Martin et al. 1997, J. Ex. Med., vol. 185, No. 7, Apr. 7, 1997, 1173-1184.
Schwartz et al., 1989, “Global Epidemiology of Meningococcal Disease,” Clin. Microbiol. Rev. 2, Supplement pp. S118-S124.
Kaczmarski, 1997, “Changing Patterns of Case Ascertainment and Trends in Meningococcal Disease in England and Whales,” Commun. Dis. Rep. Rev. 7:R55-59.
Scholten et al., 1993, “Meningococcal Disease in the Netherlands, 1958-1990: A Steady Increase in the Incidence Since 1982 Partially Caused by New Serotypes and Subtypes ofNeisseria meningitidis,” Clin. Infect. Dis. 16:237-246.
Cruz et al., 1990, “Serotype-specific Outbreak if Group B Meningococcal Disease in Iquique, Chile,” Epidemiol. Infect. 105:119-126.
Armand et al., 1982, “Tetravalent meningococcal; Polysaccharide Vaccine Groups A, C, Y, W 135: Clinical and Serological Evaluation,” J. Biol. Stand. 10:335-339.
Liebermann et al., 1996, “Safety and Immunogenicity of a Serogroups A/CNeisseria meningitidisOligosaccharide-Protein Conjugate Vaccine in Young Children,” JAMA 275(19):1499-1503.
Wyle et al., 1972, “Immunologic Response on Man to Group B Meningococcal Polysaccharide Vaccines,” J. Infect. Dis. 126(5):514-522.
Finne et al., 1983, “Antigenic Similarities Between Brain Components and Bacteria Causing Meningitis,” Lancet 355-357.
De Moraes et al., 1992, “Protective Efficacy of a Serogroup B Meningococcal Vaccine in Sao Paulo, Brazil” Lancet 340:1074-1078.
Bjune et al., 1991, “Effect of Outer Membrane Vesicle Vaccine Against Group B Meningococcal Disease in Norway,” Lancet 338:1093-1096.
Martin et al., 1997, “Highly ConservedNeisseria meningitidesSurface Protein Confers Protection against Experimental Infection,” J. Exp. Med. 185(7):1173-1183.
Lissolo et al., 1995, “Evaluation of Transferrin-Binding Protein 2 within the Transferrin-Binding Protein Complex as a Potential Antigen for Future Meningococcal Vaccines,” Inf. Immun. 63(3):884-890.
Saukkonen et al., 1989, “Comparative Evaluation of Potential Components for Group B Meningococcal Vaccine by Passive Protection in the Infant Rat and in vitro Bactericidal Assay,” J.T. Vaccine 7:325-328.
Ross et al., 1987, “Killing ofNeisseria meningitidisby Human Neutrophils: Implications for Normal and Complement-Deficient Individuals,” J. Infect. Dis. 155(6):1266-1275.
“Selection of Immunogenic Peptides for Antisera Production,”Current Protocols in Immunology, John Wiley & Sons, 1991, units 9.3.1-9.3.5.
Geysen et al., “Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid,”Proc. Nat. Acad. Sci. USA, Jul. 1984, vol. 81, pp. 3998-4002.
Reece et al., “Scanning for T helper epitopes with human PBMC using pools of short synthetic peptides,”Journal of Immunological Methods, 1994, vol. 172, No. 2, pp. 241-254.
Reece et al., “Mapping the Major Human T Helper Epitopes of Tetanus Toxin,”The Journal of Immunology, 1993, vol. 151, pp. 6175-6184.
“Synthesis of Multipe Peptides on Plastic Pins,”Current Protocols in Immunology, John Wiley & Sons, 1997, units 9.7.1-9.7.19.
Arnon et al., “Structural basis of antigenic specificity and design of new vaccines,”The FASEB Journal, Nov. 1992, vol. 6, pp. 3265-3274.
Wedege, et al., “Immune Responses against Major Outer Membrane Antigens of Neisseria meningitidis in Vaccinees and Controls Who Contracted Meningococcal Disease during the Norwegian Serogroup B Protection Trial,”Infection and Immunity, Jul. 1998, vol. 66, No. 7, pp. 3223-3231.
Bouchet, et al., “Immunological Variants of the Aerobactin-Cloacin DF13 Outer Membrane Protein Receptor IutA among Enteric Bacteria,”Infection and ImmunityInfection and Immunity, Jul. 1994, vol. 62, No. 7, pp. 3017-3021. •.
Niman, et al., “Generation of protein-reactive antibodies by short peptides is an event of high frequency: Implications for the structural basis of immune recognition,”Proc. Natl. Acad. Sci. USA, Aug. 1983, vol. 80, pp. 4949-4953.
Neisseria meningitidis, Contig 316 (p. 423-430) from Sanger Database located at file 1997-12-15-NM.dbs (636 pages), Dec. 15, 1997, URL=ftp://ftp.sanger.ac.uk/pub/pathogens
m/old—data/1997-12-15NM.dbs, download date Aug. 5, 2009.
Parkhill et al., “Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491,”Nature404:502-506, Mar. 30, 2000.
Pizza et al., “Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome Sequencing,”Science287:1816-1820, Mar. 10, 2000.
Tettelin et al., “Complete Genome Sequence ofNeisseria meningitidisSerogroup B Strain MC58,”Science287:1809-1815, Mar. 10, 2000.

Affiliated with

Also associated with

Rating

BASB054 polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with BASB054 polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and BASB054 polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4232070